These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 11557490

  • 1. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Rogers CA, Holt HA, Wootton M, Bowker KE.
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
    [Abstract] [Full Text] [Related]

  • 2. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
    MacGowan A, Rogers C, Holt HA, Wootton M, Bowker K.
    J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
    [Abstract] [Full Text] [Related]

  • 3. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.
    MacGowan AP, Bowker KE, Wootton M, Holt HA.
    J Antimicrob Chemother; 1999 Dec; 44(6):761-6. PubMed ID: 10590276
    [Abstract] [Full Text] [Related]

  • 4. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
    Bowker KE, Wootton M, Rogers CA, Lewis R, Holt HA, MacGowan AP.
    J Antimicrob Chemother; 1999 Nov; 44(5):661-7. PubMed ID: 10552983
    [Abstract] [Full Text] [Related]

  • 5. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA, Ariano RE, Iacovides H, Sun S, Harding GK.
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I, Cars O.
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [Abstract] [Full Text] [Related]

  • 7. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG, Roberts D, Waltky A, Laing N, Nichol K, Smith H, Noreddin A, Bellyou T, Hoban DJ.
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
    Mattoes HM, Banevicius M, Li D, Turley C, Xuan D, Nightingale CH, Nicolau DP.
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L, Manzor O, Pawlak J, Belian B.
    Int J Antimicrob Agents; 2005 Jul; 26(1):81-4. PubMed ID: 15951159
    [Abstract] [Full Text] [Related]

  • 11. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.
    MacGowan AP, Bowker KE, Wootton M, Holt HA.
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1560-4. PubMed ID: 10390203
    [Abstract] [Full Text] [Related]

  • 12. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    MacGowan AP, Rogers CA, Holt HA, Bowker KE.
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG, DeCorby M, Noreddin A, Mendoza C, Cumming A, Nichol K, Wierzbowski A, Hoban DJ.
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [Abstract] [Full Text] [Related]

  • 17. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [Abstract] [Full Text] [Related]

  • 18. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
    Zhanel GG, Yachison C, Nichol K, Adam H, Noreddin AM, Hoban DJ, Karlowsky JA.
    J Antimicrob Chemother; 2012 Jul; 67(7):1706-11. PubMed ID: 22467630
    [Abstract] [Full Text] [Related]

  • 19. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
    Joyanes P, Pascual A, Giménez MJ, García I, Aguilar L, Perea E.
    Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
    [Abstract] [Full Text] [Related]

  • 20. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
    Prieto J, Aguilar L, Fuentes F, Giménez MJ, Alou L, Dal-Ré R, Sörgel F, Frías J.
    Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.